Scholarlink

<p>The release rate of curcumin (CU) was controlled by developing a new and suitable formulation using an anti-solvent co-precipitation method. Layer-by-layer nanoparticles of xanthan (XA) and cholesterol (CHO) were successfully fabricated as a composite drug co-delivery system of curcumin (CU) and sodium diclofenac (DI) with a lipophilic core of CHO and an outer hydrophilic biopolymer coating of XA. The Box-Behnken experimental design was used for drug formulation and optimization to achieve maximum loading capacity (LC) and encapsulation efficiency (EE). According to the zeta potential results, the surface charge of nanoparticles was close to that of xanthan (-18.8&#xa0;mV), which can approve that the nanoparticles were properly coated with xanthan, while cholesterol precursor formed the core cavity of composite drug. The results showed that EE and LC were 68.07% and 11.48% for CU and 97.60% and 14.32% for DI, respectively. The thermal stability measurements showed that the retention rate of CU and DI in CU-DI/CHO-XA nanoparticles increased, after exposure to 75, 85, and 95&#xa0;°C for 30&#xa0;min. The results of the prolonged stability after two months demonstrated that the retention rate was increased by increasing the amount of xanthan gum. The results demonstrated that the maximum CU release from fabricated LBL nanoparticle after 60&#xa0;min in simulated gastric fluid was 19.26%, whereas its maximum release in simulated intestinal fluid after 120&#xa0;min was 82.28%. Therefore the desired CU release in simulated intestinal fluid can be effectively controlled by adjusting the composition of LBL nanoparticles.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Polymer-lipid nanocomposite for enhanced controlled release of curcumin and diclofenac sodium

  • 期刊论文

  • 发表日期：

    2026年4月28日

查看全文
  • Fatemeh Khoshtarash,
  • Mohammad Nader Lotfollahi

摘要

The release rate of curcumin (CU) was controlled by developing a new and suitable formulation using an anti-solvent co-precipitation method. Layer-by-layer nanoparticles of xanthan (XA) and cholesterol (CHO) were successfully fabricated as a composite drug co-delivery system of curcumin (CU) and sodium diclofenac (DI) with a lipophilic core of CHO and an outer hydrophilic biopolymer coating of XA. The Box-Behnken experimental design was used for drug formulation and optimization to achieve maximum loading capacity (LC) and encapsulation efficiency (EE). According to the zeta potential results, the surface charge of nanoparticles was close to that of xanthan (-18.8 mV), which can approve that the nanoparticles were properly coated with xanthan, while cholesterol precursor formed the core cavity of composite drug. The results showed that EE and LC were 68.07% and 11.48% for CU and 97.60% and 14.32% for DI, respectively. The thermal stability measurements showed that the retention rate of CU and DI in CU-DI/CHO-XA nanoparticles increased, after exposure to 75, 85, and 95 °C for 30 min. The results of the prolonged stability after two months demonstrated that the retention rate was increased by increasing the amount of xanthan gum. The results demonstrated that the maximum CU release from fabricated LBL nanoparticle after 60 min in simulated gastric fluid was 19.26%, whereas its maximum release in simulated intestinal fluid after 120 min was 82.28%. Therefore the desired CU release in simulated intestinal fluid can be effectively controlled by adjusting the composition of LBL nanoparticles.